Your Money or Your Life: Patient on $50,000-a-Week Cancer Drug Fears Leaving Behind Huge Medical Debt
When Medicare stops paying for a pricey drug that prolongs life, an Ohio man considers giving up treatment to spare his family enormous debt.
Drugs
321-340 of 1,323 results
-
-
Era of 鈥楩ree鈥 Covid Vaccines, Test Kits, and Treatments Is Ending. Who Will Pay the Tab Now?
Insurers, employers, and taxpayers will all be affected as drug manufacturers move these products to the commercial market.
A Health-Heavy State of the Union
Episode 284President Joe Biden鈥檚 2023 State of the Union address leaned heavily on health care issues. Biden took a victory lap for recent accomplishments like capping prescription drug costs for seniors on Medicare. He also urged Congress to make permanent the boosted premium subsidies under the Affordable Care Act, and he sparred with Republicans on threats to cut Social Security and Medicare. Also this week, both sides in the abortion debate are bracing for a court decision out of Texas that could, at least temporarily, make the abortion pill mifepristone illegal nationwide. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Kate Baicker of the University of Chicago about a possible middle ground in the effort to get universal health insurance coverage.
-
Centene Agrees to $215 Million Settlement With California for Alleged Medicaid Overbilling
The nation鈥檚 largest Medicaid insurer denies wrongdoing after the California attorney general鈥檚 office investigated it for inflating prescription drug costs.
-
鈥榃e Ain鈥檛 Gonna Get It鈥: Why Bernie Sanders Says His ‘Medicare for All’ Dream Must Wait
As he takes the reins of the Senate Health, Education, Labor & Pensions Committee, the independent from Vermont and implacable champion of 鈥淢edicare for All鈥 maps out his strategy for negotiating with Republicans 鈥 and Big Pharma.
By Arthur Allen -
The Pill Club Reaches $18.3 Million Medicaid Fraud Settlement With California
The online women鈥檚 pharmacy agreed to pay $15 million to the state Department of Justice and $3.3 million to the Department of Insurance over claims it overbilled Medi-Cal.
By Don Thompson -
Decisions by CVS and Optum Panicked Thousands of Their Sickest Patients
Pharmacy closures by two of the biggest home infusion companies point to grave shortages and dangers for patients who require IV nutrition to survive.
By Arthur Allen -
A Technicality Could Keep RSV Shots From Kids in Need
The Vaccines for Children program, which buys more than half the pediatric vaccines in the U.S., may not cover the RSV shot for babies because it鈥檚 not technically a vaccine.
By Arthur Allen -
Some Addiction Treatment Centers Turn Big Profits by Scaling Back Care
Private equity groups are cashing in on rising rates of alcohol and drug addiction in the U.S. But they aren鈥檛 necessarily investing in centers with the best treatment standards, and they often cut extra services.
Part II: The State of the Abortion Debate 50 Years After 鈥楻oe鈥
Episode 282In Part II of this special two-part episode, Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Sarah Varney of KHN join KHN chief Washington correspondent Julie Rovner to discuss how the abortion debate has evolved since the Supreme Court overturned the nationwide right to abortion in 2022, and what might be the flashpoints for 2023. Also, for extra credit, the panelists recommend their most memorable reproductive health stories from the last year.
-
FDA Experts Are Still Puzzled Over Who Should Get Which Covid Shots and When
A single booster seems to prevent death and hospitalization in most people, but protection from the current vaccines wanes within months. FDA experts say they need to know more from the Centers for Disease Control and Prevention to decide the best long-term strategy.
By Arthur Allen -
Montana Pharmacists May Get More Power to Prescribe
Supporters of a proposed law say it would fill a health provider gap in rural areas, while doctors worry it will give pharmacists power outside the scope of their education.
By Keely Larson Part I: The State of the Abortion Debate 50 Years After ‘Roe’
Episode 281In Part I of this special two-part episode, Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Sarah Varney of KHN join KHN chief Washington correspondent Julie Rovner to discuss how the abortion debate has evolved since the Supreme Court overturned the nationwide right to abortion in 2022, and what might be the flashpoints for 2023. Also in this episode, Rovner interviews Elizabeth Nash of the Guttmacher Institute, about changing reproductive policies in the states.
-
What Older Americans Need to Know About Taking Paxlovid
Covid-19 continues to hit seniors with disproportionate severity. Experts say Paxlovid is an effective therapy that is being underprescribed for people 65 and older.
-
Postcard From San Francisco
The Biggest, Buzziest Conference for Health Care Investors Convenes Amid Fears the Bubble Will Burst
This year鈥檚 JPMorgan confab, the first since covid鈥檚 chilling effect on such gatherings, was full of energy and enthusiasm. But it was also marked by questions about the future of health care investment.
By Darius Tahir -
California Attorney General Sues Drugmakers Over Inflated Insulin Prices
California Attorney General Rob Bonta is taking three major drugmakers and three distributors to court, alleging the companies illegally raised prices at the expense of diabetes patients.
By Angela Hart and Samantha Young GOP House Opens With Abortion Agenda
Episode 279Leaders of the new Republican-led U.S. House kicked off their legislative agenda with two bills supported by anti-abortion groups. While neither is likely to become law, the move demonstrates how abortion will continue to be an issue in Washington. Meanwhile, as open enrollment for the Affordable Care Act nears its end in most states, the number of Americans covered by the plans hits a new high. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico, and Sarah Karlin-Smith of the Pink Sheet join KHN鈥檚 Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
Behavioral Telehealth Loses Momentum Without a Regulatory Boost
As flexible treatment options spurred by the covid pandemic wane, patients relying on medications classified as controlled substances worry that without action to extend the loosened rules, it鈥檒l be harder to get their meds.
By Darius Tahir -
NY Docs Are Now Required to Prescribe Naloxone to Some Patients on Opioid Painkillers
This strategy 鈥 now in place in at least 10 states 鈥 is part of an effort to curb accidental opioid overdose deaths by patients who take these powerful medications.
-
Journalists Recap Coverage of Gun Violence, Drug Imports, and Mental Health
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.